

## Claims:

5 1. The use of Org 33245 as defined in the description for the manufacture of a contraceptive or HRT agent wherein Org 33245 is to be administered intermittently, the intermission between each pair of sequentially administered dosage units of anti-progestagen being more than one day.

10 2. A use according to claim 1, characterised in that the intermittent administration of Org 33245 takes place as an addition to progestagen-only therapy.

15 3. The use of Org 33245 for the manufacture of a medicament for minimizing uterine bleeding in a female using a progestin-only pharmaceutical preparation, characterized in that the anti-progestagen is Org 33245 as defined in the description.

20 4. A use according to any of the preceding claims, characterised in that a dosage of Org 33245 is to be administered 1-7 days during a cycle of 28-32 days, wherein one dosage marks the end of a cycle and the optional other dosages are to be administered regularly divided over the remaining days of the cycle.

25 5. A contraceptive kit providing means (a) for the daily administration of a progestagen and means (b) for the intermittent administration of an anti-progestagen, wherein the latter means (b) comprises as the anti-progestagen the compound Org 33245 as defined in the description.

6. A combined means for the dosage of a progestagen and an anti-progestagen, characterised in that the anti-progestagen is Org 33245 as defined in the description.

A2  
13

7. A method of contraception comprising daily administering to a female of child-bearing age a contraceptively effective amount of a progestagen and intermittently administering an anti-progestagen, wherein the anti-progestagen is Org 33245 as defined in the description.

5

8. A method of treatment of irregular or breakthrough uterine bleeding in a female using a progestagen-only preparation, comprising intermittently administering an anti-progestagen, wherein the anti-progestagen is Org 33245 as defined in the description.

10

9. A method according to claim 7 or 8, wherein the anti-progestagen is administered on 1-4 days in a cycle of 28-32 days.

15  
WDRB